The Ryazan plant will create a plant for the production of vaccines that are not represented in Russia

© RIA Novosti / Igor Taraborrelli in fotomontagen. Archival photoThe Ryazan plant will create a plant for the production of vaccines that are not represented in Russia© RIA Novosti / Igor Taraborrelli the image Bank

Ryazan plant «FORT», the largest enterprise in Eastern Europe in the field of Immunobiology will create a plant for the production of vaccines that are not represented in Russia, said on Wednesday the regional government.

Between the government of the Ryazan region and LLC «FORT» acts of the investment agreement regarding the granting of priority status to a project and government support, which was extended until 2022. Wednesday, December 20, Ryazan region Governor Nikolai Lyubimov visited the scientific-production complex «FORT», examined the production shops and laboratories of the plant and got acquainted with the full cycle production of influenza vaccines. According to the Governor, is a high-tech modern production, not inferior to Western businesses.

«The regional government is supporting the company as a priority investment project. Now our task is to help at the Federal level to resolve certain issues in order that the plant could increase the production of vaccines and to switch to new drugs. It is not a quick process, but, nevertheless, there is a chance to accelerate,» said Nikolai Lyubimov.

The head of the region noted that the plant will be provided in the future.

«We will continue to support the company, because there are Ryazantsev. In addition, the production develops and is ready to grow even faster. This company can be proud of and set an example,» said the Governor.

The President of the company «FORT» Anton Katlinsky said the efficiency of interaction with the government of the Ryazan region: from 2015, the plant produced almost 30 million doses of vaccines against influenza.

«For us, this interaction is extremely important. Over the past three years we have doubled production. I think we will maintain this pace for the next two years and in addition move on to a qualitatively new stage of development associated with the expansion of the range. This is a very important product, not only for us but also for epidemiological security of our country,» said Katlinsky.

According to the Director of scientific-industrial complex Paul Vandysheva, the company plans to transfer production technologies of medicines domestic and foreign manufacturers, as well as development of own innovative vaccines. «Infrastructure capabilities allow enterprises to create a new plant to localise the production of vaccines that are not represented in Russia,» said Vandyshev.

OOO «FORT» – scientific-industrial complex, which fully complies with the requirements of international standard GMP. «FORT» is engaged in development, manufacturing and marketing of biological medicinal products for prevention of infectious diseases, as well as a number of unique products in those therapeutic areas where there is the greatest in need – immunology, rheumatology, Nephrology, and Oncology. The main products of the plant – influenza vaccine «, Ultrex» (developed) and «Savegrp». In the epidemiological season 2017-2018 «FORT» put 19.5 million doses of vaccines for the national vaccination calendar.

Other news from the region read here >>